Skip to main content
. 2017 Oct 11;39(2):134–145. doi: 10.1093/carcin/bgx114

Figure 3.

Figure 3.

BITC treatment decreases RUNX2 expression in human breast cancer cells. (A) Representative confocal images (×63 objective magnification in oil) depicting levels of RUNX2 (green) in MDA-MB-231, MCF-7 and SK-BR-3 cells after 24-h treatment with DMSO or the indicated doses of BITC. Nuclei were stained with DRAQ5 (blue). (B) Quantitative real-time polymerase chain reaction analysis for RUNX2 mRNA expression in MDA-MB-231, MCF-7, and SK-BR-3 cells after 24 h of treatment with DMSO or the indicated doses of BITC. Columns indicate average of triplicate samples of a representative experiment, and bars indicate standard deviation. P value was determined by one-way analysis of variance (ANOVA) with Dunnett’s adjustment. (C) Western blotting for RUNX2 and sRANKL proteins using whole cell lysates of T47D/shRUNX2Dox cells after 24-h treatment with Dox and/or BITC. The numbers above bands represent fold changes of proteins relative to DMSO-treated control. (D) Quantitation of osteoclasts from co-culture of RAW264.7 (RAW) and T47D / shRUNX2Dox after 6 days of treatment with DMSO or the indicated doses of BITC. Columns indicate average of triplicate samples of a representative experiment, and bars indicate standard deviation. P value was determined by one-way ANOVA followed by Bonferroni’s multiple comparison test. Consistent results were obtained from at least two independent experiments.